The Treatment of Primary IgA Nephropathy
Dongxu Song, Shengqiang Yu* and Changlin Mei
Division of Nephrology, Nephrology Institute of PLA, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China
- *Corresponding Author:
- Shengqiang Yu
Division of Nephrology
Nephrology Institute of PLA
Shanghai Chang zheng Hospital
Second Military Medical University, Shanghai, China
E-mail: [email protected]
Received Date: November 03, 2013; Accepted Date: November 30, 2013; Published Date: December 04, 2013
Citation: Song D, Yu S, Mei C (2013) The Treatment of Primary IgA Nephropathy. J Nephrol Ther 3:144. doi:10.4172/2161-0959.1000144
Copyright: © 2013 Song D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
IgA Nephropathy (IgAN) is a very common glomerulonephritis worldwide, especially in Asia, which is an important cause of progressive kidney disease with 25–30% of patients developing end-stage renal disease within 20 years of diagnosis. IgA nephropathy can be in different age bracket onset, but mainly in adults. The treatment of primary IgA nephropathy we mentioned in this article is only for adults. The optimal treatment for IgAN remains poorly defined. The current treatment depends on the assessment of proteinuria, blood pressure, estimated Glomerular Filtration Rate (eGFR) and pathological features, including antiproteinuric and antihypertensive therapy, corticosteroids, immunosuppressive agents, fish oil and tonsillectomy. Compounded by the relative lack in IgAN of Randomized Controlled Trials (RCTs),
there is no consensus on the use of corticosteroids, immunosuppressive agents, fish oil and tonsillectomy for treatment. The treatment of primary IgA Nephrology was reviewed from these aspects in this article.